Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
Clinical trial NCT03564691 · COMPLETED
Trial details
- NCT number
- NCT03564691
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-11
- Primary completion
- 2025-09-26
- Enrollment
- 470
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.